Call to arms: need for radiobiology in molecular radionuclide therapy

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Verheijen RH, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24(4):571–8.

    Article  CAS  PubMed  Google Scholar 

  4. 4.

    Bodei L, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Del Prete M, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728–42.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Pouget JP, et al. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12.

    Article  Google Scholar 

  7. 7.

    European Association of Nuclear Medicine Internal Dosimetry Task Force Report, Treatment planning for molecular radiotherapy: potential and prospects. Flux G, Stokke C., editors. 2017.

  8. 8.

    European Council Directive. 2013/59/Euratom of 5 December 2013 laying down basic safety standards for protections against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Off J Eur Union. 2014.

  9. 9.

    Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9(5):351–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Nonnekens J, et al. Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib. Theranostics. 2016;6(11):1821–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge Mark Konijnenberg, Emmanuel Deshayes, and Fijs van Leeuwen for their comments during preparation of this letter.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Samantha Y. A. Terry.

Ethics declarations

Conflict of interest

Author ST declares that she has no conflict of interest. Author JN has an investigator-initiated project contract with Advanced Accelerator Applications, a Novartis company. Author AA declares that she has no conflict of interest. Author SB declares that she has no conflict of interest. Author MdJ has an investigator-initiated project contract with Advanced Accelerator Applications, a Novartis company. Author BC is a paid consultant for Molecular Targeted Radiopharmaceuticals. Author J-PP declares that he has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Terry, S.Y.A., Nonnekens, J., Aerts, A. et al. Call to arms: need for radiobiology in molecular radionuclide therapy. Eur J Nucl Med Mol Imaging 46, 1588–1590 (2019). https://doi.org/10.1007/s00259-019-04334-3

Download citation